TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an announcement.
Ondine Biomedical Inc. has been invited to present its health economic data on Steriwave nasal photodisinfection at the International Conference on Prevention & Infection Control (ICPIC) 2025 in Geneva. The presentation will demonstrate how Steriwave significantly reduces costs associated with surgical site infections, improving patient outcomes and offering substantial savings for healthcare systems. This recognition highlights Ondine’s commitment to advancing infection control with cost-effective solutions, reinforcing its position in the healthcare industry.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those from multidrug-resistant organisms. The company has a range of investigational products based on its proprietary photodisinfection technology, with its nasal photodisinfection system, Steriwave®, approved in multiple countries and undergoing clinical trials in the US.
Average Trading Volume: 364,027
Technical Sentiment Signal: Buy
Current Market Cap: £66.64M
Learn more about OBI stock on TipRanks’ Stock Analysis page.